These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17620377)

  • 1. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
    Odenholt I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3311-6. PubMed ID: 17620377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.
    Thabit AK; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2016 Jan; 60(1):222-8. PubMed ID: 26482306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin: in vitro activity against staphylococci in a biofilm model.
    Gander S; Kinnaird A; Finch R
    J Antimicrob Chemother; 2005 Aug; 56(2):337-43. PubMed ID: 15972312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006).
    Hatano K; Matsuzaki K; Sato Y; Kobayashi I; Yamaguchi K
    J Antibiot (Tokyo); 2007 Nov; 60(11):709-12. PubMed ID: 18057701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Lubenko IY; Strukova EV; Smirnova MV; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Pawlak J; Johnson LB
    J Antimicrob Chemother; 2007 Aug; 60(2):406-9. PubMed ID: 17586562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
    Marconescu P; Graviss EA; Musher DM
    Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.
    Farrell DJ; Krause KM; Benton BM
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):275-9. PubMed ID: 21353951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA; Nichol K; Zhanel GG
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
    Lepak AJ; Zhao M; Andes DR
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
    Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
    Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model.
    Cha R; Rybak MJ
    J Antimicrob Chemother; 2004 Jul; 54(1):259-62. PubMed ID: 15150172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.
    Clouse FL; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4521-4. PubMed ID: 17908947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.